Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model
- 21 September 2015
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 14 (2) , 223-234
Abstract
In recent decades, accumulating evidence from both animal and clinical studies has suggested that a sufficiently activated immune system may strongly augment various types of cancer treatment, including photodynamic therapy (PDT). Through the generation of reactive oxygen species, PDT eradicates tumors by triggering localized tumor damage and inducing anti-tumor immunity. As the major component of anti-tumor immunity, the involvement of a cell-mediated immune response in PDT has been well investigated in the past decade, whereas the role of humoral immunity has remained relatively unexplored. In the present investigation, using the photosensitizer BAM-SiPc and the CT26 tumor-bearing BALB/c mouse model, it was demonstrated that both cell-mediated and humoral adaptive immune components could be involved in PDT. With a vascular PDT (VPDT) regimen, BAM-SiPc could eradicate the tumors of ∼ 70% of tumor-bearing mice and trigger an anti-tumor immune response that could last for more than 1 year. An elevation of Th2 cytokines was detected ex vivo after VPDT, indicating the potential involvement of a humoral response. An analysis of serum from the VPDT-cured mice also revealed elevated levels of tumor-specific antibodies. Moreover, this serum could effectively hinder tumor growth and protect the mice against further re-challenge in a T-cell-dependent manner. Taken together, these results show that the humoral components induced after BAM-SiPc-VPDT could assist the development of anti-tumor immunity.Keywords
This publication has 71 references indexed in Scilit:
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathThe EMBO Journal, 2012
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatmentCancer Immunology, Immunotherapy, 2011
- Photodynamic therapy enhancement of anti-tumor immunityPhotochemical & Photobiological Sciences, 2011
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessmentBritish Journal of Cancer, 2009
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPCJournal of Controlled Release, 2009
- Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- Photodynamic activity of BAM‐SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour‐bearing nude miceBritish Journal of Pharmacology, 2008
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006